# Evaxion A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Evaxion A/S). ## Overview Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform. The company is based in Copenhagen, Denmark and operates as a research-driven developer of immunology-based therapeutics for infectious disease, cancer, and autoimmune applications. ## Products & services • AI-Immunology™ platform for immune target discovery • Therapeutic vaccine candidates for cancer • Vaccine programs for infectious diseases • Preclinical and clinical-stage drug candidates • Immunology and antigen design services for partners - **AI-Immunology™ platform** (20%) — AI-based discovery tools used to identify immune targets and design candidates. - **Cancer vaccine programs** (30%) — Therapeutic vaccine candidates aimed at oncology indications such as AML. - **Infectious disease vaccine programs** (20%) — Vaccine development programs for infectious disease targets including polio-related work. - **Autoimmune disease programs** (15%) — Research programs applying the platform to autoimmune disease targets. - **Partnered R&D and grants** (15%) — Collaborative research activity and grant-supported development work. - AI-Immunology™ platform for immune target discovery - Therapeutic vaccine candidates for cancer - Vaccine programs for infectious diseases - Preclinical and clinical-stage drug candidates - Immunology and antigen design services for partners ## Customers Evaxion's direct customers are typically pharmaceutical, biotechnology, and research partners that license, fund, or collaborate on vaccine and immunology programs. It also depends on grant providers and public-interest funders for selected research projects, while future commercial demand would come from healthcare partners and developers seeking novel therapeutic candidates. - **Pharmaceutical partners** (primary) — License or co-develop vaccine and drug candidates discovered through the platform. - **Biotechnology collaborators** (primary) — Work with Evaxion on early-stage programs and platform validation. - **Grant foundations** (secondary) — Fund specific public-health research projects such as vaccine design work. - **Academic and research partners** (secondary) — Use Evaxion's AI-enabled discovery approach for translational immunology work. - Pharma partners seeking licensed vaccine or immunology assets - Biotech collaborators funding early-stage co-development - Grant-making foundations supporting public-health programs - Research institutions needing AI-based antigen discovery - Future commercial partners for oncology and infectious disease programs ## Geography Evaxion is headquartered in Copenhagen, Denmark, but its equity listing and investor base are international. The business is research-led and therefore relies more on partner networks, grants, and clinical collaboration channels than on physical manufacturing footprint. - **Denmark** (100%) — Headquarters and core operating base - Headquartered in Copenhagen, Denmark - Operates as a Danish biotech with global partnering potential - U.S. market access through Nasdaq listing and investor base - Clinical and research work can involve multinational collaborators - Geographic exposure is driven more by partners than sales offices ## Strategy Evaxion's strategy centers on advancing its AI-Immunology™ platform to generate differentiated vaccine and immunology candidates across multiple disease areas. It also emphasizes external validation through partners, investors, and research collaborations to broaden awareness of the platform and support program progression. - **Advance pipeline candidates** (medium-term) — Progressing candidates is required to create value from the discovery platform. - **Broaden platform validation** (short-term) — External proof points improve credibility with partners and investors. - **Expand disease-area reach** (long-term) — Applying the platform across multiple indications increases optionality. - Advance AI-Immunology™ as a target discovery engine - Progress vaccine candidates through preclinical and clinical stages - Build external partnerships to validate the platform - Expand use of the platform beyond one therapeutic area - Use collaborative programs to fund and de-risk development ## Risks Evaxion faces typical clinical-stage biotech risks: programs may fail in preclinical or clinical testing, timelines can extend materially, and value depends on successfully advancing a small number of assets. The company also carries liquidity, foreign exchange, and valuation-estimate risk because it has limited recognized revenue and relies on funding, grants, collaborations, and equity-linked instruments. - **Program failure in preclinical or clinical development** [high] — Value depends on a small pipeline advancing successfully through testing. - **Liquidity risk** [high] — The company has not recognized meaningful revenue and depends on external funding. - **Foreign exchange risk** [medium] — International collaboration and reporting can create currency mismatches. - **Warrant and share-based compensation volatility** [medium] — Equity-linked instruments and stock compensation can move reported expenses and liabilities. - Clinical trial and preclinical failure risk for vaccine candidates - Dependence on funding, grants, and external collaboration support - Foreign exchange exposure from international operations and reporting - Liquidity risk due to limited recurring revenue - Valuation risk from warrants and share-based compensation ## Accounting Evaxion's financial reporting is shaped by the absence of recurring product revenue and by judgment-heavy estimates around going concern, warrants, and share-based compensation. Because the business is clinical-stage, development spending, grant revenue timing, and fair-value measurements can materially affect period-to-period comparability. - **Revenue recognition** — Affects comparability because revenue can be intermittent or nominal - **Going concern** — Can influence disclosures and investor assessment of funding runway - **Warrants and derivative liabilities** — May create non-cash gains or losses in the income statement - **Share-based compensation** — Raises reported R&D and G&A expense without cash outflow - No revenue recognized in the reported interim period - Grant revenue is recognized when qualifying funding conditions are met - Going concern assessment is a key judgment area - Warrants may require derivative liability fair-value remeasurement - Share-based compensation affects operating expense and equity --- *Last updated: 2026-09-28T12:03:34.853333+00:00*